Life Technologies to Help Identify up to 20,000 Human Remains Found in Libya's Mass Graves

Life Technologies to Help Identify up to 20,000 Human Remains Found in Libya's
                                 Mass Graves

  PR Newswire

  GLASGOW, Scotland, January 30, 2013

GLASGOW, Scotland, January 30, 2013 /PRNewswire/ --

  Humanitarian project will set up infrastructure, provide expert training,
                         validate and process samples

Life Technologies Corporation (NASDAQ: LIFE) today announced it will provide a
complete laboratory solution to identify an estimated 20,000 human remains
found in various mass graves in Libya following the uprising of 2011 and to
address missing persons cases from the 42-year regime of Muammar Gaddafi.
This identification work is expected to take several years.

Life Technologies, a leader in forensic DNA technologies, will provide the
infrastructure, including the expertise, training, and the forensic
instruments and materials to validate the workflow and process DNA samples
through its Dubai-based distributor Integrated Gulf Biosystems (IGB) .

"It is our hope that many families will find the answers to what happened to
their loved ones," said Peter Silvester, President, Life Technologies, Europe,
Middle East & Africa. "By providing the laboratory setup and forensic
expertise we will help train Libyan scientists in the very latest instruments,
technology and protocols to enable them in their work and help promote
reconciliation in Libya."

Life Technologies will create two separate DNA lines - one geared toward
reference samples and the second focusing on processing samples from human
remains. Fifty-thousand samples will be processed per year. Human remains
samples will be processed using PrepFiler® BTA chemistry optimized to isolate
DNA from bones and teeth in combination with AmpFlSTR® NGM SElect™ PCR
Amplification Kit and MiniFiler™ Kit, designed for heavily degraded samples.
Reference samples will be processed using direct amplification technology
combining Copan NUCLEIC-CARD™ with NGM SElect™ Express .

The laboratory will utilise the latest generation of genetic analysers and
ancillary equipment and will be functionally validated under the quality
assurance standards and guidelines required by the ASCLAD-LAB, SWGDAM and ISO
17025. Some training of Libyan scientists will take place in the United
States under the direction and supervision of Dr. Arthur Eisenberg , a world
renowned forensic scientist, leading up to the lab's opening in Tripoli.

"The University of North Texas Health Science Center, with its extensive
experience in the identification of missing persons and human decedents, is
extremely pleased to partner with Life Technologies in the training of the
Libyan forensic scientists to help them complete their mission," said Dr.
Eisenberg, Director of the UNT Center for Human Identification .

The humanitarian project is funded in part by Repsol , a Spanish-based oil
company which donated to the Libyan government through its foundation, $2.5
million in 2012 to help establish a state-of-the-art laboratory to identify
and generate profiles from human remains and references from associated
relatives of missing people.

AmpFlSTR ^® NGM SElect ^™ PCR Amplification Kit, Copan NUCLEIC-CARD™,
MiniFiler ^™ Kit and NGM SElect ^™ Express are for forensic and paternity use
only. PrepFiler ^® BTA is for research use only, not for use in diagnostic

Life Technologies Corporation (NASDAQ: LIFE ) is a global biotechnology
company with customers in more than 160 countries using its innovative
solutions to solve some of today's most difficult scientific challenges.
Quality and innovation are accessible to every lab with its reliable and
easy-to-use solutions spanning the biological spectrum, with more than 50,000
products for agricultural biotechnology, translational research, molecular
medicine and diagnostics, stem cell-based therapies, forensics, food safety
and animal health. Its systems, reagents and consumables represent some of the
most cited brands in scientific research including: Ion Torrent™, Applied
Biosystems®,Invitrogen™, Gibco®, Ambion®, Molecular Probes® and Novex®.Life
Technologiesemploys approximately 10,400 people and upholds its ongoing
commitment to innovation with more than 4,000 patents and exclusive licenses.
LIFE had sales of$3.7 billionin 2011. Visit us at our website: .

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about our anticipated
results that involve risks and uncertainties. Some of the information
contained in this press release, including, but not limited to, statements as
to industry trends and Life Technologies' plans, objectives, expectations and
strategy for its business, contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results or events
to differ materially from those expressed or implied by such forward-looking
statements. Any statements that are not statements of historical fact are
forward-looking statements. When used, the words "believe," "plan," "intend,"
"anticipate," "target," "estimate," "expect" and the like, and/or future tense
or conditional constructions ("will," "may," "could," "should," etc.), or
similar expressions, identify certain of these forward-looking statements.
Important factors which could cause actual results to differ materially from
those in the forward-looking statements are detailed in filings made byLife
Technologies with the Securities and Exchange Commission.Life Technologies
undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.

Contact: Media Contacts: David Robertson, Corporate Communications, Europe
Middle East & Africa; Life Technologies, Email:,
Tel: +44(0)141-814-5889; Patty Zamora, Corporate Communications (US), Life
Technologies Email:, Tel: +1-7604767818
Press spacebar to pause and continue. Press esc to stop.